PubMed Health⌕ Search

Biomedical subjects

N Goldblum

Publications and source records attributed to N Goldblum.

14 recordsLinked to original sources
PubMed1990

Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus.

We have previously shown that the presence of the EBV genome and active EBV infection in some Burkitt's lymphoma cell lines confer the susceptibility of HIV-1 infection in spite of the absence of surface CD4 receptors in these cells. In the present study we used an EBV genome negative Burkitt's lymphoma B-cell line, DG75, transfected with three different subgenomic fragments of EBV expressing the nuclear antigens (EBNA1 and EBNA2) and the latent membrane protein (LMP), respectively. Immunofluorescence analysis demonstrated CD4 expression in more than 90% of the EBNA1, EBNA2 and LMP transfected cell lines, whereas the antigen could only be detected in less than 4% of the parental DG75 cell line. Unlike the wild type DG75 line, the three transfected cell lines were shown to be susceptible to HIV-1 by both IFA and production of virions. Northern blotting of poly(A) selected mRNA of the four cell lines and hybridization to a human CD4 cDNA (pT4B) demonstrated a 3 kb band in all three EBNA1, EBNA2 and LMP transfected cells as well as in the wild type DG75 cells. Approximate quantification indicates equivalent level of T4 mRNA expression in the transfected cell lines as compared to T-cell lines (Hut-78, H9-9).

Antigens, Viral↗
PubMed1986

Use of a combined DTP-polio vaccine in a reduced schedule.

A five-year serologic follow-up and a four-year monitoring of the polio and pertussis morbidity in an area immunized with a 2 + 1 dose schedule of a combined DTP-Po vaccine have shown that: the individual protection against polio measured by the presence of neutralizing antibody persists at a very adequate level five years after the first booster; after three years of a steady high proportion of children with pertussis antibody, a considerable drop is observed and in about 28% of individuals agglutinin levels of less than 1:20 were found five years after booster; the community protection against paralytic poliomyelitis and pertussis is satisfactory up to four years after the introduction of the program. Continuation of immunization with a 2 + 1 dose schedule at a maximal coverage and close seroepidemiologic surveillance are necessary in order to draw definite conclusions, because of the potentially strong impact of very dynamic ecological factors present in our geopolitical area upon the agent-host interrelationship.

Agglutination Tests↗
PubMed1985

A modified schedule for routine pertussis immunization.

As part of a study with a quadruple inactivated vaccine (diphtheria-pertussis-tetanus-polio), the serologic response to the pertussis antigen was investigated in infants at the age of routine immunization, inoculated with one of the following two regimens: either 0.5 ml vaccine at 2 and 3 1/2 months and a booster six months later, or an identical dose of vaccine given at 2, 4 and 6 months and a booster at the age of 12 months. A pertussis agglutination titer of greater than or equal to 1:10 was considered an immune response to the administration of the antigen. Two basic doses of pertussis antigen induced an immune response in about 92% of children, which was very close to that following three basic doses. A 100% seroconversion was observed in both groups one month after the booster dose, and geometric mean values were high in both regimens. At one and two years after the booster, the pertussis agglutinins were present in 100% of children of both groups, with higher geometric mean values in the group given the three basic doses regimen.

Age Factors↗
PubMed1979

Antibody to poliovirus in older children and young adults in Israel and the use of poliovaccines for the immunization of the seronegatives.

This report represents preliminary results of a more extensive study which is presently being carried out in Israel. The main aims of this study were twofold: (1) to carry out a survey of the state of immunity of children of various ages and of teenagers to the three poliovirus types and (2) to compare the antibody response of the seronegatives to the two kinds of presently available poliovaccines, the oral poliovaccine (O. P. V., Savin Vaccine) and the inactivated poliovaccine (I. P. V., Salk Vaccine).

Adolescent↗
PubMed1978

Concanavalin A receptors on the surface membrane of lymphocytes from patients with Burkitt's lymphoma, other malignant lymphomas, leukaemia and lymphoma cell lines.

Lymphocytes isolated from the peripheral blood and tumour tissues of patients with African Burkitt's lymphoma (BL) showed a reduced cap-forming ability and increased agglutinability by concanavalin A (con A) compared to normal lymphocytes. Lymphocytes from the blood of patients with chronic lymphocytic leukaemia, Hodgkin's disease and other malignant lymphomas showed a similar reduction in cap formation and increase in agglutination compared to normal lymphocytes, lymphocytes from patients with carcinoma, and lymphocytes from patients with non-malignant disorders. The cap formation of lymphocytes from a healthy donor or a lymphoma patient was independent of the source from which the cells were isolated, e.g., lymph-node, spleen or blood. Lymphoma cell lines established from tumours of BL patients and lymphoblastoid cell lines originating from other sources also exhibited an increased agglutination and reduced cap formation with con A. Further studies indicated that EBV-carrying human lymphoid lines had a reduced cap-forming ability compared to EBV-negative lines.

Burkitt Lymphoma↗
PubMed1977

Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75).

The isolation and establishment in vitro of a hitherto undescribed type of lymphocyte designated D.G.-75 is reported. The original inoculum was derived from the pleural effusion of a child with a primary abdominal lymphoma, which clinically and histologically resembled Burkitt's lymphoma. In addition to the absence of the EBV genome and EBV receptors, this line possesses a number of other properties which distinguish it from previously described lymphoblastoid cell lines. It has different growth characteristics and morphology; does not form EAC or E rosettes (representative of B and T) cell surface markers, respectively); possesses IgM-kappa immunoglobulins on the cell surface (B lymphocyte), has an unusually high cap-forming ability and low agglutinability with fluorescent concanavalin A. One homologue of the No.14 chromosome pair possesses extra chromatin material as revealed on chromosome banding. This abnormal chromosome marker is similar to that described in biopsies and cultured tumor cells from patients with African Burkitt's lymphoma.

Agglutination Tests↗
PubMed1976

Concanavalin A receptors on the surface membrane of lymphocytes from patients with African Burkitt's lymphoma and lymphoma cell lines.

Lymphocytes isolated from the peripheral blood and from tumor tissues of patients with African Burkitt's lymphoma have been studied for cap formation and agglutinability by Concanavalin A (Con A). Peripheral blood from healthy adult persons served as a normal control and blood from patients with carcinoma served as a non-lymphoma control. These studies included 29 patients with Burkitt's lymphoma, 93 with carcinoma, and 105 healthy adult persons, as well as tumor tissues from 13 patients with Burkitt's lymphoma. The great majority of the carcinomas were from the face and neck regions. Lymphocytes from the blood of the majority of patients with Burkitt's lymphoma, as well as those from tumor tissues, exhibited a reduced cap-forming ability (2-6%) and increased Con-A-induced agglutinability compared to lymphocytes from healthy normal donors and from patients with carcinoma, although some of the lymphocytes from patients with carcinoma had a somewhat lower range of cap formation than the lymphocytes from healthy donors. No difference was observed in the interaction with Con A of lymphocytes from the different types of carcinoma studied. Eight lymphoid cell lines were established in our laboratory from the tumor tissues of patients with Burkitt's lymphoma. The cap-forming ability and agglutinability by Con A of these lines was examined and compared to those of the "classical" lymphoma lines: Raji, Daudi and P3HR1. All cell lines exhibited an increased Con-A-induced agglutinability and a reduced cap-forming ability compared to normal lymphocytes, except for P3HR1 cells which exhibited a cap-forming ability of 15-20%. These findings are discussed in relation to the association of the lymphocytes with malignancy and as a possible aid in the differential diagnosis between malignant lymphomas and other diseases.

Agglutination↗
PubMed1975

Concanavalin A receptors on the surface membrane of lymphocytes from patient's with Hodgkin's disease and other malignant lymphomas.

Concanavalin A (Con A) induces movement of its receptors on the cell surface membrane. This induction results in a concentration of Con A site complexes on one pole of the cell to form a cap. A marked difference was found in the mobility of Con A receptor between lymphocytes from normal persons and lymphocytes from patients with Hodgkin's disease and other malignant lymphomas. Lymphocytes isolated from tonsils of patients undergoing tonsillectomy and from axillary lymph nodes of breast cancer patients exhibited approximately 30% of cells with caps, which is identical with the cap formation ability of normal lymphocytes. In biopsy material from patients with Hodgkin's disease and other malignant lymphomas, a significant decrease in the ability of the lymphocytes to form caps was observed. This difference in the mobility of Con A sites was even more pronounced in lymphocytes isolated from the peripheral blood. In 123 patients with Hodgkin's disease and other malignant lymphomas, cap formation ranged between 3 and 12%. The ability of cells, from a normal donor or a lymphoma patient, to form caps was independent of the source from which the lymphocytes were isolated, e.g., lymph node, spleen, or blood. Lymphocytes from patients with lymphoma were also agglutinated by Con A to a higher degree than normal lymphocytes. These findings are discussed in relation to the association of the lymphocytes with these malignancies and as a possible aid in their differential diagnosis.

Agglutination↗